Source:http://linkedlifedata.com/resource/pubmed/id/10396321
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1999-7-15
|
pubmed:abstractText |
Following preoperative administration of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with colorectal cancer, histologic antitumor effects as well as pyrimidine nucleoside phosphorylase (PyNPase) activities in cancerous tissues were examined. Fifty-five patients were randomly divided into two groups: Twenty-five patients received 5'-DFUR orally at a daily dose of 800 mg for 3 weeks before operation (Group A) and twenty-nine received no medication (Group B). PyNPase activities in cancerous tissues obtained from resected specimens in Group A and B were 49.7 +/- 21.6 and 66.6 +/- 40.0 U/mg prot, respectively, which were significantly higher than 25.5 +/- 14.1 and 22.1 +/- 11.2 U/mg prot in normal colorectal tissues. No significant difference was observed in PyNPase activities in cancerous tissues between Group A and B. PyNPase activities in cancerous tissues in Group A were no different either from 59.2 +/- 40.0 U/mg prot in biopsy specimens before administration of 5'-DFUR. Histologic anti-tumor effects were as follows: Grade 2, 1 case Grade 1b, 5; Grade 1a, 10; and Grade 0, 9. Although no correlation was observed between antitumor effects and PyNPase activities in cancerous tissues, antitumor effects of 2 cases in which PyNPase activities in cancerous tissues before administration of 5'-DFUR showed more than 100 U/mg prot were Grade 2 and 1b, respectively.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Floxuridine,
http://linkedlifedata.com/resource/pubmed/chemical/Pentosyltransferases,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidine Phosphorylases,
http://linkedlifedata.com/resource/pubmed/chemical/doxifluridine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
939-43
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:10396321-Adenocarcinoma,
pubmed-meshheading:10396321-Administration, Oral,
pubmed-meshheading:10396321-Aged,
pubmed-meshheading:10396321-Antineoplastic Agents,
pubmed-meshheading:10396321-Colorectal Neoplasms,
pubmed-meshheading:10396321-Drug Administration Schedule,
pubmed-meshheading:10396321-Floxuridine,
pubmed-meshheading:10396321-Humans,
pubmed-meshheading:10396321-Middle Aged,
pubmed-meshheading:10396321-Pentosyltransferases,
pubmed-meshheading:10396321-Pyrimidine Phosphorylases
|
pubmed:year |
1999
|
pubmed:articleTitle |
[Antitumor effect of 5'-DFUR and PyNPase activity in colorectal cancer].
|
pubmed:affiliation |
Dept. of Surgery, Osaka Prefectural General Hospital.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Randomized Controlled Trial
|